Copenhagen, Denmark-based bio-industrial company developing proprietary Binding ProteinsTM, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and antimicrobial resistance, Bactolife raised EUR 30 million in Series C. The round took place on August 8, 2023. ATHOS led the financing for the firm. Meanwhile, Bill & Melinda Gates Foundation and existing investors, such as Novo Holdings, also joined in the Series C funding.
Purpose of financing for Bactolife
With the latest financing, Bactolife has plans to further advance its most mature projects towards commercial launch. The company also intends to strengthen its technology platform and upscaling capabilities.
The company has plans to retain its first-mover advantage to transform human and animal health with target-specific Binding Proteins™.
What the company’s official has to add
Sebastian Søderberg, CEO of Bactolife, said, “We are very pleased and humbled by the continued confidence that investors have shown us, especially in times of geopolitical uncertainty and market turmoil. The funding allows us to increase our investments in our project pipeline, technology platform, organisation and upscaling capabilities. Further, it will enable Bactolife to accelerate our partnering efforts with world-leading companies and commercialise our first product concepts for humans and animals.”
What the investors have to comment
Julian Zachmann, Investment Manager at ATHOS, further said, “Infectious diseases and increasing antimicrobial resistance are amongst the biggest threats to global health and development. We are committed to addressing this challenge and believe in Bactolife’s targeted solutions.”
In addition, Aleks Engel, Partner, Novo Holdings, said, “The successful Series A is another validation of Bactolife’s impressive achievements and opportunity for the future. Bactolife is a great example of the strong Danish biotech ecosystem, as its technology platform originates from a Danish University and is then further enabled by pioneering Danish biotech companies and talents. This bodes well for the future of not only Bactolife but the Danish biotech sector as a whole. Further, I am very pleased that the international investors share our enthusiasm for finding solutions to the global AMR crisis. Combatting antimicrobial resistance requires all hands on deck.”
About the company
In 2017, Founders Andreas Laustsen, David Kauffmann, Mads Laustsen, Per Falholt, and Sandra Wingaard Thrane launched the company. Bactolife is a Danish industrial biotech company with approx. 40 employees. Bactolife leverages its proprietary Binding Protein technology to develop novel biological solutions. It strengthens the gut microbiome and helps solve the daunting challenge of antimicrobial resistance (AMR) development, as well as the general burden of infectious diseases.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
